{"url":"https://newsforagent.com/news/2026-11-04/iaso-bio-fucaso-singapore-launch","markdown_url":"https://newsforagent.com/news/2026-11-04/iaso-bio-fucaso-singapore-launch.md","title":"IASO Bio Launches FUCASO CAR-T Therapy in Singapore","headline":"IASO Bio and Pills and Pokes Launch FUCASO, Singapore's First BCMA CAR-T Therapy","description":"IASO Bio and Pills and Pokes launched FUCASO in Singapore on November 3, 2026, after HSA approval in June, with Cancer Drug List coverage from December 1.","section":"Product Launches","published_at":"2026-11-04T05:42:55+00:00","modified_at":"2026-11-04T05:42:55+00:00","author":"News Desk","key_takeaways":["IASO Bio and Pills and Pokes hosted the FUCASO launch event in Singapore on November 3, 2026.","Singapore's HSA approved FUCASO in June 2026 for adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy.","FUCASO joins Singapore's Cancer Drug List effective December 1, 2026, opening coverage through public and commercial funds."],"companies":[{"name":"IASO Biotherapeutics","is_primary":true,"profile_url":null,"website":"http://www.iasobio.com"}],"source":{"publisher":"PR Newswire","title":"IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub","url":"https://www.prnewswire.com/news-releases/iaso-bio-hosts-fucaso-singapore-launch-event-marking-the-official-commercial-landing-of-chinas-original-fully-human-bcma-car-t-cell-therapy-in-southeast-asias-healthcare-hub-302928816.html"},"other_sources":[],"tags":["Product Launches","IASO Biotherapeutics"],"body_markdown":"IASO Bio and its Singapore partner Pills and Pokes hosted a launch event in Singapore on November 3 for FUCASO, the first BCMA-targeted CAR-T cell therapy approved in the country. The therapy won Health Sciences Authority approval in June 2026 for adults with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent, [PR Newswire](https://www.prnewswire.com/news-releases/iaso-bio-hosts-fucaso-singapore-launch-event-marking-the-official-commercial-landing-of-chinas-original-fully-human-bcma-car-t-cell-therapy-in-southeast-asias-healthcare-hub-302928816.html) reported.\n\n## How the FUCASO Launch Unfolded in Singapore\n\nThe event, themed \"Expanding New Possibilities in the Treatment of Relapsed/Refractory Multiple Myeloma,\" gathered hematology-oncology clinicians from Singapore, local partners and investors. Professor Chng Wee Joo of the National University Cancer Institute, Singapore, gave the welcome address and closing remarks. Professor Chandramouli of Singapore General Hospital presented on the treatment landscape and unmet needs in R/R MM, and Professor Chen Wenming of Beijing Chaoyang Hospital discussed treatment sequencing and patient selection for BCMA-targeted therapy.\n\nThe first commercial infusion of FUCASO was completed at Parkway Cancer Centre two months after approval. The patient, an adult with R/R MM who had received four prior lines of therapy, achieved complete response and remains in good condition, according to the announcement on [IASO Bio's website](http://www.iasobio.com). The company said the case validated its cross-border model, which spans patient screening and leukapheresis, cold-chain logistics, manufacturing and release at its China facility, and cold-chain return to Singapore for infusion.\n\n\"The launch event in Singapore marks the full commercial take-off of FUCASO at the healthcare hub of Southeast Asia,\" said Zhang Hua, Chief Business Officer and Senior Vice President of IASO Bio. Gail Chang, Co-founder and Chief Executive Officer of Pills and Pokes, said: \"FUCASO is the first BCMA CAR-T cell therapy approved in Singapore, and Singapore is its first market outside Greater China.\"\n\nFUCASO was added to Singapore's Cancer Drug List effective December 1, 2026, following evaluation by the Agency for Care Effectiveness under the Ministry of Health. From that date, eligible patients can obtain coverage for treatment costs through a financing network of public and commercial funds.\n\n## Earlier IASO Bio Milestones Before the Launch\n\nIASO Bio presented first-in-human Phase 1 data of RD140, a BCMA/GPRC5D dual-targeted CAR-T, at the 2026 IMS Annual Meeting in September 2026, PR Newswire reported. In 9 heavily pretreated patients, the overall objective response rate was 88.9% and MRD negativity was 88.9%, with no neurotoxicity observed.\n\nThe FDA cleared the IND application for IASO208, a CD20-targeted in vivo CAR-T therapy, in September 2026, with the therapy expected to advance directly into a Phase Ib clinical study in the U.S., PR Newswire reported. In August 2026, IASO Biotechnology completed its acquisition of Singapore-based cell therapy company MediSix Therapeutics, integrating its PEBL technology platform and R&D pipeline with IASO Bio's manufacturing and commercialization capabilities, the Laotian Times reported.\n\n## FUCASO Coverage Start Date\n\nFUCASO's inclusion in Singapore's Cancer Drug List takes effect on December 1, 2026, when eligible patients can access coverage for treatment costs through public and commercial funds.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}